GH Research (GHRS) Non-Current Assets (2021 - 2025)
GH Research's (GHRS) quarterly Non-Current Assets came in at $2.3 million in Q4 2025, down 93.38% year-on-year from $34.0 million in Q4 2024, and down 68.83% quarter-over-quarter from $7.2 million in Q3 2025.
GH Research (GHRS) Non-Current Assets (2021 - 2025) Analysis & Trends
GH Research's Non-Current Assets history runs 5 years deep, the most recent figure standing at $2.3 million for Q4 2025.
- On a quarterly basis, Non-Current Assets fell 93.38% year-over-year to $2.3 million in Q4 2025; TTM through Dec 2025 was $54.8 million, a 71.13% decrease from a year earlier, with the FY2025 full-year figure at $2.3 million, down 93.38% from the prior year.
- Non-Current Assets slipped to $2.3 million in Q4 2025 per GHRS's latest filing, from $7.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $122.1 million in Q4 2021 and bottomed at $73000.0 in Q3 2021.
- The 5-year median for Non-Current Assets is $39.4 million (2024), against an average of $41.2 million.
- Across the five-year window, Non-Current Assets surged 104272.84% in 2023 and tumbled 93.38% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $122.1 million in 2021, then decreased by 29.7% to $85.8 million in 2022, then decreased by 27.51% to $62.2 million in 2023, then slumped by 45.27% to $34.0 million in 2024, then tumbled by 93.38% to $2.3 million in 2025.
- Per Business Quant, the three latest GHRS Non-Current Assets figures stand at $2.3 million (Q4 2025), $7.2 million (Q3 2025), and $19.5 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | GH Research | 1.69 Bn | 1.69 Bn | - | 2.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.25 Mn |
| Sep 30, 2025 | 7.23 Mn |
| Jun 30, 2025 | 19.55 Mn |
| Mar 31, 2025 | 25.79 Mn |
| Dec 31, 2024 | 34.05 Mn |
| Sep 30, 2024 | 44.67 Mn |
| Jun 30, 2024 | 54.07 Mn |
| Mar 31, 2024 | 57.11 Mn |
| Dec 31, 2023 | 62.21 Mn |
| Sep 30, 2023 | 68.53 Mn |
| Jun 30, 2023 | 73.87 Mn |
| Mar 31, 2023 | 84.54 Mn |
| Dec 31, 2022 | 85.82 Mn |
| Sep 30, 2022 | 84,000.00 |
| Jun 30, 2022 | 86,000.00 |
| Mar 31, 2022 | 81,000.00 |
| Dec 31, 2021 | 122.08 Mn |
| Sep 30, 2021 | 73,000.00 |